Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech IncfiledCriticalJanssen Biotech Inc
Publication of AR115424A1publicationCriticalpatent/AR115424A1/en
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents
(AREA)
Abstract
Se describen anticuerpos anti-CD33 y fragmentos de unión al antígeno de estos y anticuerpos biespecíficos anti-CD33 / anti-CD3 o fragmentos de unión al antígeno de estos. También se describen ácidos nucleicos que codifican los anticuerpos, composiciones que componen los anticuerpos, métodos para producir anticuerpos y métodos para usar los anticuerpos para tratar o prevenir enfermedades, tales como el cáncer. Reivindicación 1: Un anticuerpo monoclonal aislado o fragmento de unión al antígeno de este que se une específicamente al dominio C2 de CD33.Anti-CD33 antibodies and antigen-binding fragments thereof and anti-CD33 / anti-CD3 bispecific antibodies or antigen-binding fragments thereof are described. Also described are nucleic acids that encode the antibodies, compositions that make up the antibodies, methods for producing antibodies, and methods for using the antibodies to treat or prevent diseases, such as cancer. Claim 1: An isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds to the C2 domain of CD33.
ARP190101403A2018-05-242019-05-24
ANTI-CD33 ANTIBODIES, ANTI-CD33 / ANTI-CD3 BIS SPECIFIC ANTIBODIES AND USES OF THEM
AR115424A1
(en)